HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 price objective on the stock.

AC Immune Stock Up 4.7 %

AC Immune stock opened at $1.88 on Thursday. AC Immune has a 52-week low of $1.77 and a 52-week high of $4.98. The firm’s fifty day moving average is $2.43 and its 200 day moving average is $2.88. The company has a market cap of $188.77 million, a price-to-earnings ratio of -4.09 and a beta of 1.49.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quinn Opportunity Partners LLC purchased a new stake in AC Immune during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP purchased a new position in shares of AC Immune during the 4th quarter worth about $36,000. Boothbay Fund Management LLC purchased a new position in shares of AC Immune during the 4th quarter worth about $38,000. RPO LLC bought a new position in AC Immune during the 4th quarter valued at about $51,000. Finally, Jane Street Group LLC purchased a new stake in AC Immune in the 4th quarter worth about $66,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.